Home » Stocks » CFRX

ContraFect Corporation (CFRX)

Stock Price: $3.95 USD -0.12 (-2.95%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $3.90 -0.05 (-1.27%) Jul 23, 7:26 PM
Market Cap 155.36M
Revenue (ttm) n/a
Net Income (ttm) -25.77M
Shares Out 28.96M
EPS (ttm) -0.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $3.95
Previous Close $4.07
Change ($) -0.12
Change (%) -2.95%
Day's Open 4.13
Day's Range 3.93 - 4.14
Day's Volume 92,025
52-Week Range 3.44 - 7.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

6 days ago - GlobeNewsWire

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

6 days ago - GlobeNewsWire

YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...

1 month ago - GlobeNewsWire

YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

1 month ago - GlobeNewsWire

Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function

1 month ago - GlobeNewsWire

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021

2 months ago - GlobeNewsWire

YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...

2 months ago - GlobeNewsWire

YONKERS, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

2 months ago - GlobeNewsWire

YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

3 months ago - GlobeNewsWire

Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021

3 months ago - GlobeNewsWire

YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatmen...

4 months ago - GlobeNewsWire

YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatmen...

4 months ago - GlobeNewsWire

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...

Other stocks mentioned: ALT, EVOK, NVAX
4 months ago - Benzinga

CARB-X and Cystic Fibrosis Foundation grant s provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections

8 months ago - GlobeNewsWire

YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), incl...

8 months ago - GlobeNewsWire

YONKERS, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DL...

10 months ago - GlobeNewsWire

Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis Initial eval...

11 months ago - GlobeNewsWire

Exebacase Phase 2 study results published in the Journal of Clinical Investigation

11 months ago - GlobeNewsWire

YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...

1 year ago - GlobeNewsWire

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia

1 year ago - GlobeNewsWire

YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

1 year ago - GlobeNewsWire

YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatmen...

1 year ago - GlobeNewsWire

YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatmen...

1 year ago - GlobeNewsWire

YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), inc...

1 year ago - GlobeNewsWire

Abstracts highlight the advancement of three new antibacterial modalities: novel native lysins, engineered lysins and amurin peptides Abstracts highlight the advancement of three new antibacterial modal...

1 year ago - GlobeNewsWire

YONKERS, N.Y., March 30, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...

1 year ago - GlobeNewsWire

YONKERS, N.Y., March 18, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), i...

1 year ago - GlobeNewsWire

YONKERS, N.Y., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

1 year ago - GlobeNewsWire

ContraFect: A Game-Changing Treatment For The Superbug MRSA

1 year ago - Seeking Alpha

YONKERS, N.Y., Feb. 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

1 year ago - GlobeNewsWire

YONKERS, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

1 year ago - GlobeNewsWire

ContraFect Corporation Is A Differentiated Infectious Disease Pick For 2020

1 year ago - Seeking Alpha

YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

1 year ago - GlobeNewsWire

Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia  Superior...

1 year ago - GlobeNewsWire

Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa Pre-Clinical Data Demonstrate Efficacy and...

1 year ago - GlobeNewsWire

YONKERS, N.Y., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatme...

1 year ago - GlobeNewsWire

YONKERS, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatme...

1 year ago - GlobeNewsWire

Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus ( MRSA) Bacteremia, including Right-Sided Endocarditis

1 year ago - GlobeNewsWire

YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLA...

1 year ago - GlobeNewsWire

YONKERS, New York, Sept. 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents ...

1 year ago - GlobeNewsWire

YONKERS, N.Y., Aug. 28, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

1 year ago - GlobeNewsWire

About CFRX

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineere... [Read more...]

Industry
Biotechnology
IPO Date
Jul 29, 2014
CEO
Roger Pomerantz
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
CFRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ContraFect stock is "Strong Buy." The 12-month stock price forecast is 14.33, which is an increase of 262.78% from the latest price.

Price Target
$14.33
(262.78% upside)
Analyst Consensus: Strong Buy